Bangladesh is on the threshold of a new breakthrough in the history of its pharmaceutical industry, raising a ray of hope for preventing serious diseases like dengue and measles, which have become common epidemics in the country.
Judging by the urgency and serious threat posed by these diseases every year, the government has swung into action. Its decision to locally develop and produce dengue, rabies and measles vaccines, along with snakebite antivenom, marks a timely and potentially transformative step for the country's public health sector.
At present, the country has been suffering from a measles outbreak, with the situation worsening due to a shortage of vaccines. For instance, seven more children died from measles and measles-like symptoms in 24 hours on Friday, taking the total number of confirmed and suspected measles deaths to 343. Additionally, nearly 7,000 measles infections have been confirmed since the first case was identified on January 4 this year.
Dengue is another epidemic that has evolved from a seasonal concern into a major public health emergency, claiming hundreds of lives and infecting thousands more every year. Last year, health officials said dengue alone caused 413 deaths and more than 100,000 infections. In 2023, dengue wreaked havoc in the country, claiming a record 1,705 lives in a single year, while the number of infections reached 321,179.
Meanwhile, snakebite is one of Bangladesh's most neglected health crises despite causing thousands of preventable deaths every year. A national survey estimates around 400,000 snakebite cases annually, leading to more than 7,500 deaths each year, many of which are preventable with timely access to antivenom.
Rabies, a fatal disease transmitted mostly through dog bites in Bangladesh, remains a significant public health concern, with deaths rising every year due to a shortage of timely vaccination. According to an estimate, in the first two and a half months of 2026, 19 deaths were registered, following 58 deaths in 2024 and 59 in 2025.
What is unfortunate is that deaths from all these diseases have increased due to a lack of vaccines, which are mostly imported in small quantities that fall far short of local demand. This is why recurring outbreaks and shortages continue to expose the fragility of Bangladesh's healthcare system.
In this context, the initiative to develop vaccines for these diseases reflects the reality that no country can afford to remain excessively dependent on imported lifesaving medicines. For this reason, the necessity of the move is undeniable.
Against this backdrop, the efforts taken by the state-owned Essential Drugs Company Limited (EDCL) to develop these vaccines deserve praise. Although the proposed investment, estimated at Tk 20-25 crore, appears modest compared to the enormous social and economic benefits, it kindles hope of curbing these preventable diseases.
With production of all four vaccines expected to begin within a year, the supply of these pharmaceuticals to government hospitals is targeted from June next year. If Bangladesh succeeds in producing these vaccines and antivenom locally, it will not only reduce costs but also ensure greater supply stability during emergencies, when imports may become uncertain.
There is also export potential for these products, as nearly 10 million vials are expected to be produced annually in Bangladesh against a local demand of about 5 million doses. Officials said this could eventually allow surplus production for export. It is a testament to the fact that Bangladesh's pharmaceutical industry has already established itself as one of the country's major success stories, meeting most domestic demand for medicines and exporting to many countries. Expanding into vaccine production could open a new frontier for the sector.
